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Abstract
No validated prognostic tool is available for predicting overall survival (OS) of patients 
with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in 
three independent cohorts of patients from five different European countries, aimed 
to develop and validate a classification prognostic score for OS in patients with stage IV 
WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the 
Istituto Nazionale Tumori (Milan, Italy; n = 515); (ii) European cohort of rare NET patients 
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included in the European RARECAREnet database (n = 457); (iii) Italian multicentric 
cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions (n = 415). 
The score was developed using data from patients included in cohort (i) (training 
set); external validation was performed by applying the score to the data of the two 
independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability 
(Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous 
vs metachronous), Ki-67, functional status and primary surgery to build the score, which 
was developed for classifying patients into three groups with differential 10-year OS: 
(I) favorable risk group: 10-year OS ≥70%; (II) intermediate risk group: 30% ≤ 10-year 
OS < 70%; (III) poor risk group: 10-year OS <30%. The Harrell C statistic was 0.661 in the 
training set, and 0.626 and 0.601 in the RARECAREnet and Italian multicentric validation 
sets, respectively. In conclusion, based on the analysis of three ‘field-practice’ cohorts 
collected in different settings, we defined and validated a prognostic score to classify 
patients into three groups with different long-term prognoses.
Introduction
Neuroendocrine tumors (NETs) are a heterogeneous 
class of neoplasms with increasing incidence worldwide 
(Fraenkel et  al. 2012, Dasari et  al. 2017). A number of 
factors including tumor histology, primary site, staging 
and proliferative index influence tumor behavior and 
patients’ survival (Panzuto et al. 2014).
Patients with NETs are classified according 
to both tumor morphology and assessment of 
proliferation according to World Health Organization 
(WHO)/European Neuroendocrine Tumor Society (ENETS) 
guidelines. Morphology is classified as well- or poorly-
differentiated; grading (G1–G2–G3) is assessed by Ki-67 
and mitotic count (Rindi et  al. 2010, Bosman 2010). In 
particular, well-differentiated (WD) NETs are considered 
indolent malignancies and are associated with a relatively 
favorable prognosis (Öberg et  al. 2012, van der Zwan 
et al. 2013, Frilling et al. 2014). However, even WDNETs 
present a marked heterogeneity in their clinical behavior 
(Pusceddu et  al. 2017). Given this variable course of 
disease, selection of the most suitable treatment (first-line 
and sequence) remains challenging.
Therefore, the development of prognostic scores 
able to classify patients according to clinical outcomes 
appears of the highest interest in current clinical 
research. Indeed, such scores may help guide treatment 
selection and, at the same time, could be used in the 
design of clinical trials (Mariani et al. 2005, Motzer et al. 
2008). Prognostic scores for OS have been specifically 
developed to assess OS in patients with gut NETs 
(Modlin et al. 2010) or gastrointestinal high-grade, G3 
neuroendocrine carcinomas (GI-NECs) (Lamarca et  al. 
2017), to predict progression-free survival of patients 
with stage IV NETs (Panzuto et al. 2017), or to predict 
disease recurrence rate after surgery in G1–G2 NETs 
(Genç et  al. 2017). However, to our knowledge, no 
validated score addresses the prognosis of WDNETs in 
terms of OS.
In this large study, conducted in three independent 
cohorts of patients from five different European countries, 
we aimed to develop and validate a classification 
prognostic score for OS in patients with stage IV WD 
G1–G2 NETs.
Patients and methods
Study design
Three retrospective cohorts were included in this study: 
(i) a training cohort of patients treated at the Istituto 
Nazionale Tumori (INT) (Milan, Italy), a referral Center 
for the treatment of oncological disease and an European 
Neuroendocrine Tumor Society (ENETS) Center of 
Excellence for the treatment of gastroenteropancreatic 
(GEP)-NETs; (ii) a European external validation cohort, 
which comprised rare NET patients included in the 
database of the pilot study of the European project 
RARECAREnet (Gatta et  al. 2017), which collected data 
on rare NETs of any site (poorly-differentiated NET of 
the lung were not in the database since they are not 
considered rare tumors) from 4 population-based cancer 
registries from 4 countries: Belgium, Slovenia, The 
Netherlands and Ireland and (iii) an Italian external 
validation multicentric cohort including only pancreatic 
NET (pNETs) patients treated at 24 different Italian 
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institutions. Approval for data collection was obtained 
independently by each institution involved as per 
local practice.
Description of the three cohorts
Training cohort
Out of a prospectively collected monocentric database 
including 1091 patients presenting with diagnosis of 
NET from 1988 to 2012 at INT, data of 515 patients were 
extracted to perform the present study if they presented 
G1–2 metastatic (stage IV) WD GEP-NETs or lung NETs at 
diagnosis. In more detail, the following primary sites were 
considered: (I) pancreatic neuroendocrine tumors, (II) 
midgut NETs (ileum appendix, caecum, jejunum, ileum, 
duodenum); (III) other GEP-NETs (stomach, rectum and 
colon except caecum); (IV) lung typical or atypical NETs 
and (V) NET of unknown primary.
NET diagnosis was confirmed at general hematoxylin 
and eosin staining histology and immunohistochemistry, 
in all cases by a dedicated pathologist (MM). Slices were 
reviewed for morphology, mitotic count and grading 
assessment in agreement with the 2010 GEP-NET WHO 
and 2015 lung NET WHO classifications (Rindi et al. 2010, 
Travis et al. 2015).
Patients were ineligible if they had a poorly-
differentiated neuroendocrine carcinoma (NEC G3) or 
had other histology such as Merkel cell carcinomas, 
pheochromocytoma/paragangliomas, large cell NEC 
(LCNC) and small-cell lung cancer (SCLC).
We investigated the prognostic impact on survival of 
different clinical parameters, including age, gender, site 
of primary tumor, resection of primary tumor, metastatic 
site, time to metastasis development, functioning or not 
functioning status. All patients were followed up until the 
end of 2015.
External validation cohorts
The same inclusion criteria applied in the training 
cohort were used to identify patients for inclusion in the 
two external validation cohorts (European and Italian 
multicentric cohorts).
The European cohort was extracted from the 
RARECAREnet pilot study. All patients were stage IV 
at diagnosis with G1–2 grading score WD GEP-NETs, 
WD of the lung and unknown primary site cancers 
were selected. In total, we included 457 patients: 155 
diagnosed in Belgium in the period 2004–2007; 168 in 
The Netherlands in the period 2005–2007 and 79 in 
Ireland and 55 in Slovenia in the period 2000–2007. 
All patients were followed up for vital status until the 
end of 2012. Therefore, patients from Netherlands 
had only seven years of follow-up, Belgium eight 
years, Ireland and Slovenia 10 years (only two patients 
contributing).
To externally validate the score in a selected cohort of 
patients with a single primary tumor site, we identified an 
Italian multicentric series of 415 patients with WD pNETs 
treated at 24 Italian Institutions from 2000 to 2015. All 
patients were followed up until the beginning of 2017.
Statistical methods
The study endpoint was OS; the time was calculated 
from the date of diagnosis to the date of death from all 
causes, with censoring at the date of last follow-up in 
living patients. OS curves were estimated by the Kaplan–
Meier method, with the log-rank test used to compare 
subgroups.
The NeuroEndocrine Prognostic Score classification 
(NEP-Score) for stage IV WD NET patients was developed 
using the data of patients included in the training set. 
Among the data made available in the institutional 
database, the a priori chosen putative prognostic covariates 
were patients’ age at metastasis detection (≤45, 46–65, 
>65  years), gender, site of primary tumor (ileum; lung; 
pancreas; other GEP-NETs – stomach, rectum and colon 
except caecum, unknown primary site), site of metastasis 
(single hepatic lesion; single extra-hepatic lesion; multiple 
hepatic lesions and multiple extra-hepatic lesions), time 
to metastasis development (synchronous, metachronous 
≤24 months, metachronous >24 months), Ki-67 (MIB-1) 
(0–2, 3–20, not specified), functional status (yes vs no) 
and primary tumor resection (yes, no). Multivariable Cox 
model analysis was carried out and a covariate backward 
selection procedure based on the Akaike Information 
Criterion was applied (Akaike 1973). No interactions 
between covariates were assessed in the selection 
procedure. Such a procedure led to exclude gender and 
site of metastasis from the initial set of 8 parameters. NEP-
Score was intended to classify patients according to their 
predicted 10-year OS. Thus, we firstly derived a covariate 
scoring system based on the 10-year OS predicted by the 
final Cox model. Then, a three-level prognostic score 
was derived for classifying patients according to their 
predicted 10-year OS: (i) favorable risk group: OS ≥70%; 
(ii) intermediate risk group: OS ≥30% and <70%; (iii) poor 
risk group: OS <30%.
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NEP-Score performance was evaluated by examining 
calibration (calibration plot) and discriminative ability 
(Harrell C index) (Harrell et al. 1996) on the training set 
(internal validation). External validation was performed 
by applying the NEP-Score to the data of the two 
independent validation cohorts and evaluating both 
calibration and discriminative ability. To obtain the 
calibration plot in the testing cohorts and to be coherent 
with the score predictions, ideally, we should have used 
the 10-year OS probabilities predicted according to the 
final Cox model fitted in the training set. However, 
while in the Italian multicentric series, the percentage of 
patients still at risk at 10 years was as high as 17%, in the 
RARECAREnet cohort, it dropped to 3% at 10 years but 
was similar to that of the Italian series at 7 years (16%). 
Thus, in the latter cohort, we truncated the OS curves at 
7 years, and we used the same cut-off for evaluating the 
NEP-Score performance.
Statistical analyses were conducted using SAS software 
(SAS Institute, Cary, NC, USA) and R software (http://
www.r-project.org/).
Additional details are reported in the Supplementary 
Materials and methods (see section on supplementary 
data given at the end of this article).
Results
Figure  1 displays the disposition of patients through 
the study period. Median follow-up (interquartile range, 
IQR) was 78 (36–131) months in the training set and 87 
(75–102) and 77 (37–130) months in the European and 
Italian validation cohort, respectively. Table  1 depicts 
patient characteristics.
In the training set, 218 patients died for any cause; 
5- and 10-year OS (95% CI) was 64.3% (59.8–69.2%) 
and 42.6% (37.0–49.0%), respectively. In the European 
validation cohorts, 330 patients died for any cause; 
5- and 7-year OS was 38.7% (34.5–43.5%) and 29.6% 
(25.5–34.3%). In the Italian validation set, 122 patients 
died for any cause; 5- and 10-year OS was 81.2% 
(76.9–85.6%) and 54.0% (47.2–61.8%).
Classification prognostic score development and 
internal validation
The results of the multivariable Cox model used to 
develop the NEP-Score are reported in Table 2, together 
with the results of the univariable Cox model including 
NEP-Score.
Table 3 shows the covariate scoring system and how 
to calculate NEP-Score. This score was able to classify 
patients into three groups with differential 10-year OS: 
(I) favorable risk group: total score ≤70 points, 10-year OS 
≥70%; (II) intermediate risk group: 70 < total score ≤ 198, 
30% ≤ 10-year OS < 70%; (III) poor risk group: total score 
≥199, 10-year OS <30%. Table  4 shows the distribution 
of training set patients and the Kaplan–Meier OS 
estimates according to the NEP-Score categories, and 
Fig. 2 (panel A) shows the OS curves. The calibration plot 
in the training cohort (Fig. 3, panel A) shows very good 
accordance between the predicted and observed 10-year 
OS probabilities. The Harrell C statistic for the Cox model 
including NEP-Score was 0.661 (95% CI: 0.592–0.730) 
that, being NEP-Score a three-level categorical variable 
incorporating the prognostic information of multiple 
variables, was slightly lower than that obtained in 
the multivariable Cox model from which NEP-Score was 
generated (0.696 vs 0.661, Table 2).
Classification prognostic score external validation
As compared with the training set, OS was poorer in 
the RARECAREnet validation set (Fig.  2, panel B); as a 
consequence, the calibration analysis (Fig.  3, panel B) 
Figure 1
Patients’ disposition in the three cohorts. GEP, gastroenteropancreatic; INT, Istituto Nazionale Tumori; NEC, neuroendocrine carcinoma; NET, 
neuroendocrine tumors; Pts, patients; WD, well differentiated. A full colour version of this figure is available at https://doi.org/10.1530/ERC-17-0489.
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showed that, when applying NEP-Score to this validation 
set, in each of the three classification prognostic score 
categories, the observed OS was slightly overestimated.
As compared with the training set, OS showed an 
improvement in the Italian multicentric validation 
set (Fig.  2, panel C); as a consequence, the calibration 
analysis (Fig. 3, panel C) showed that NEP-Score slightly 
underestimated the observed OS when applied to this 
validation set of patients. The Harrell C statistic for the 
three-levels score was 0.626 (95% CI: 0.571–0.681) and 
0.601 (95% CI: 0.505–0.697) in the RARECAREnet and 
Italian multicentric validation sets, respectively.
Table 1 Characteristics of 515 training set patients, 457 RARECAREnet cohort patients and 414 Italian series cohort patients.
  
Training set No. (%)
 
RARECAREnet cohort No. (%)
Italian multicentric 
cohort No. (%)
Year of diagnosis
  <2000 159 (30.9) – 18 (4.3)
  ≥2000 356 (69.1) 457 (100.0) 426 (95.7)
Gender
  Male 284 (55.1) 239 (52.3) 226 (54.5)
  Female 231 (44.9) 218 (47.7) 189 (45.5)
Age at metastasis (years)
  Median, IQR 57, 45–65 65, 56–64 56, 45–65
  <45 129 (25.0) 30 (6.6) 104 (25.1)
  46–65 269 (52.2) 204 (44.6) 209 (50.4)
  >65 117 (22.7) 223 (48.8) 102 (24.6)
Primary tumor classification site
  Other GEP-NET+ 81 (15.7) 192 (42.0) –
  Lung (typical and atypical carcinoids) 69 (13.4) 54 (11.8) –
  Ileum 135 (26.2) 92 (20.1) –
  Pancreatic 139 (27.0) 58 (12.7) 415 (100.0)
  Unknown 91 (17.7) 61 (13.3) –
Functioning status
  Yes 123 (23.9) 14 (3.1) 71 (17.1)
  No 392* (76.1) 443 (96.9) 344 (82.9)
Chromogranine A (pathological level ULN)
  Yes 56 (10.9) – 225 (54.2)
  No 185 (35.9) – 143 (34.5)
  Not performed 209 (40.6) – 34 (8.2)
  Unknown 65 (12.6) – 13 (3.1)
Ki-67 (MIB-1)
  0–2 206 (40.0) 347 (75.9) 117 (28.2)
  3–20 149 (28.9) 110 (24.1) 290 (69.9)
  Missing 160 (31.1) – 8 (1.9)
Primary tumor surgery
  Yes 298 (57.9) 234 (51.2) 236 (56.9)
  No 217 (42.1) 223 (48.8) 179 (43.1)
Metastasis
  Syncronous 447 (86.8) 457 (100.0) 296 (71.3)
  Metachronous ≤24 months 27 (5.2) – 41 (9.9)
  Metachronous >24 months 41 (8.0) – 78 (18.8)
Metastasis site (stage IV)
  Liver (single metastasis) 18 (3.5) – 158† (38.1)
  Liver (multiple metastasis) 212 (41.2) – –
  Nodes (single site of metastases) 9 (1.7) – 14† (3.4)
  Nodes 37 (7.2) – –
  Lung† 12 (2.3) – –
  Other (single site of metastases) 16 (3.1) – 10 (2.4)
  Multiple site (including liver) 189 (36.7) – 220 (53.0)
  Multiple site (excluding liver) 22 (4.3) – 10 (3.1)
Peptide receptor radionuclide therapy
  Yes 37 (7.2) – 104 (25.1)
  No 478 (92.8) – 311 (74.9)
*4 missing data imputed with modal value; +stomach, rectum and colon except caecum; †single or multiple.
IQR, interquartile range; ULN, upper level of normality.
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Complementary analysis
The NEP-Score considered only the prognostic 
characteristics of patients at diagnosis and did not analyze 
the impact of the medical treatments received by the 
patients during the course of the disease.
However, since peptide receptor radionuclide therapy 
(PRRT) has been shown to prolong OS in midgut NET 
(interim analysis of the NETTER-1 trial) (Strosberg et  al. 
2017), unlike other approved therapeutic agents that 
improved progression-free survival only (Yao et al. 2016 
2017, Faivre et al. 2017, Pavel et al. 2017, Rinke et al. 2017), 
we speculated that this effect could also be observed in the 
Italian multicentric validation set enrolling only pNET 
patients. Moreover, only 7.2% of patients in the training 
set had received PRRT, vs 25.1% of the multicenter Italian 
validation set (Table 1).
Therefore, as a complementary analysis, we extracted 
a subgroup of 311 patients not receiving PRRT from the 
Italian multicentric validation set in order to exclude any 
potential effect of PRRT on survival. OS curves obtained 
on patients not receiving PRRT in the Italian validation set 
are shown in Fig. 4, panel A. 5- and 10-year OS (95% CI) 
were 78.0% (72.8–83.7%) and 49.2% (41.0–58.9%), 
respectively. As compared with the calibration plot of the 
whole Italian validation set, estimated OS is closer to the 
observed OS (Fig. 4, panel B). No events were observed in 
the favorable risk group. The Harrell C statistic was 0.626 
(95% CI: 0.571–0.681) in this subset.
Discussion
NETs are an extremely heterogeneous class of neoplasms, 
and several different tumor- and patient-related factors 
influence prognosis. Therefore, scores able to define 
prognosis would be of the highest interest in current 
clinical research and practice on NETs.
Current treatments for G1–2 metastatic WDNETs 
include somatostatin analogues (SSAs), chemotherapy, 
targeted therapies and PRRT, without a precise definition 
of the best sequence (Kulke et  al. 2008, Rinke et  al. 
2009, Yao et  al. 2010, 2011, 2016, 2017, Pavel et  al. 
2011, Strosberg et al. 2012, 2017). Treatment selection is 
therefore based on the evaluation of tumor and patient 
characteristics – also because of the lack of randomized 
Table 2 Results of the multivariable Cox model including the selected covariates and used to develop the prognostic score on 
training set patients and of the univariable model including the prognostic score.
Hazard ratio 95% CI P Value
Multivariable Cox model used to develop the prognostic score
  Primary tumor surgery <0.001
  Yes vs no 0.39 0.26–0.57
  Age at metastasis (years) 0.030
  46–65 vs ≤45 1.31 0.90–1.89
  >65 vs ≤45 1.74 1.15–2.65
  Primary tumor classification site 0.005
  Other GEP-NET vs ileum 2.51 1.53–4.13
  Carcinoid lung vs ileum 2.00 1.19–3.34
  Unknown vs ileum 1.52 0.89–2.60
  Pancreatic vs ileum 1.76 1.10–2.82
  Metastasis timing 0.032
  Metachronous ≤24 months vs synchronous 1.98 1.15–3.42
  Metachronous >24 months vs synchronous 1.44 0.87–2.36
  Ki-67 (Mib-1) 0.003
  Missing vs 0–2 1.72 1.23–2.42
  3–20 vs 0–2 1.12 0.76–1.67
  Functional status 0.073
  Yes vs no 1.35 0.97–1.88
  C statistic (95% confidence interval): 0.696 (0.625–0.767)
Univariable Cox model including prognostic score
  Prognostic score† <0.0001
  Intermediate vs favorable risk group 3.08 1.80–5.26
  Poor vs favorable risk group 6.87 4.06–11.64
  C statistic (95% confidence interval): 0.661 (0.592–0.730)
†Favorable risk group: total score ≤70 points, 10-year OS ≥70%. Intermediate risk group: 70 < total score ≤ 198, 30% ≤ 10-year OS < 70%. Intermediate risk 
group: 70 < total score ≤ 198, 30% ≤ 10-year OS < 70%. Poor risk group: total score ≥199, 10-year OS <30%. The total score was calculated according to Fig. 2.
CI, confidence interval; GEP, gastroenteropancreatic.
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trials due to the heterogeneity and rarity of disease – in a 
tailored approach.
Although most WD-lung NETs and patients with 
WD-GEP-NET are characterized by an indolent disease, 
a minority of them show a poor outcome and shorter 
survival with an unpredictable clinical course. However, 
with standard therapeutic options, median progression-
free survival is generally extended by less than six months 
due to the development of resistance, and benefit is 
mainly limited to disease control, which eventually results 
in disease progression.
Noteworthy, we still do not know what biological, 
pathological or clinical features might be able to 
characterize this subgroup of ‘poor risk’ patients within 
the G1–G2 classification and therefore be able to provide 
a recommendation for the best algorithm for treatment.
To this end, no prognostic tools have been specifically 
developed to estimate OS probability in specific subgroups 
of patients with G1–2 NETs. In this large study, based on 
the analysis of three ‘field-practice’ cohorts collected in 
different settings, we defined and validated a prognostic 
score able to classify stage IV WD NET patients into three 
groups with different long-term prognosis (10-year OS). 
NEP-Score takes into account some immediately retrievable 
factors, namely age, primary tumor site, metastasis 
(synchronous vs metachronous), Ki-67, the presence 
of functioning status and prior surgical removal of the 
primary tumor, and therefore, may be easily applicable 
in clinical practice. According to the factors mentioned 
earlier, this score stratifies patients into a favorable risk 
group (OS ≥70%), an intermediate risk group (30–70%) 
and a poor risk group (<30%). Of note, molecular factors 
influencing prognosis are not yet validated for NETs and 
therefore they were not considered for the development 
of this tool. Moreover, given the limited proportion of 
patients in the training set with a single metastatic lesion 
(8.3%) or extra-hepatic disease only (18.6%), we decided 
not to include them in the multivariable Cox model used 
to develop the prognostic score. Therefore, we analyzed 
single vs multiple sites of disease. However, no specific 
substaging of stage IV exists to help quantify metastatic 
disease, and therefore, this parameter would be difficult 
to utilize in a scoring system such as ours. NEP-Score was 
developed in a monocentric cohort of patients referring 
Table 3 Covariate scoring system and NeuroEndocrine Prognostic Score classification (NEP-Score).
Covariate scoring system
Age at metastasis (years) Scores
  <45 0
  46–65 28
  >65 58
Primary tumor classification site Scores
  Ileum 0
  Unknown 44
  Pancreatic 59
  Carcinoid lung 72
  Other GEP-NET 97
Metastasis timing Scores
  Synchronous 0
  Metachronous >24 months 38
  Metachronous ≤24 months 72
Ki-67 (Mib-1) Scores
  0–2 0
  3–20 12
  Missing 57
Functional status Scores
  No 0
  Yes 32
Primary tumor surgery Scores
  No 100
  Yes 0
Total score 10-year OS Prognostic groups
Stage IV WD NET patients prognostic score classification (NEP-score)
  T ≤ 70 ≥70% Favorable risk group
  70 < T ≤ 198 30% ≤ OS < 70% Intermediate risk group
  T ≥ 199 <30% Poor risk group
OS, overall survival; total score T, sum of the covariate scores; WD GEP-NET, well differentiated gastroenteropancreatic neuroendocrine tumor.
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to an Excellence Center for the treatment of NETs, thus 
ensuring a high level of reliability of data homogeneity. 
Then, NEP-Score was validated in two external cohorts, 
the former European and the latter Italian multicentric 
group. The European cohort showed a lower OS than in 
the training set, which is not surprising. It is well known 
that OS at the population level is lower than that in 
clinical series, since population data include information 
on all hospital settings (general and specialized), as well 
as on patients not accessing the hospital, and of any age. 
Our OS were coherent with those reported in a similar 
population-based study (Yao et  al. 2008). Thus, such a 
characteristic is independent of the prognostic variables 
and was associated with a lower baseline OS which, 
in turn, affected the calibration results (i.e. NEP-Score 
slightly overestimated the observed OS). Nevertheless, 
the calibration plot points were aligned and parallel to 
the reference line, indicating that the predictions were 
systematically too high and the covariates had a similar 
effect in the validation set. On the other hand, patients 
in the Italian validation cohort showed a higher OS 
when compared with those of the validation set and 
the calibration plot points were aligned and parallel to 
the reference line, thus indicating that the predictions 
were systematically too low, and even in this case, the 
covariates had a similar effect in the validation set.
We cannot rule out that this difference can be justified, 
at least in part, by the inclusion of pNET patients solely 
Table 4 Distribution of training and validation set patients 
and Kaplan–Meier overall survival estimates according to the 
NEP-Score categories.
 
 
 
Training set 
(n = 515)
 
RARECAREnet 
cohort (n = 457)
Italian series 
cohort 
(n = 415)
Whole series
  5-year, %  
(95% CI)
64 (60–69) 39 (35–44) 81 (77–86)
  10-year, %  
(95% CI)
43 (37–49) 30 (26–34)† 54 (47–62)
NEP-Score*
  Log-rank test  
P value
<0.001 <0.001 0.001
  Favorable risk 
group n (%)
99 (19) 77 (17) 9 (2)
  5-year, % 
(95% CI)
92 (86–98) 64 (54–75) 100–
  10-year, % 
(95% CI)
75 (64–88) 39 (26–59)† 100–
  Intermediate risk 
group n (%)
236 (46) 216 (47) 264 (64)
  5-year, % 
(95% CI)
68 (62–76) 44 (38–52) 86 (81–91)
  10-year, % 
(95% CI)
51 (42–61) 26 (18–36)† 59 (51–68)
  Poor risk  
group n (%)
180 (35) 164 (36) 142 (34)
  5-year, % 
(95% CI)
45 (38–54) 20 (14–27) 68 (59–79)
  10-year, % 
(95% CI)
18 (12–27) 5 (1–22)† 38 (26–57) 
*Favorable risk group: total score ≤70 points, 10-year overall survival 
≥70%. Intermediate risk group: 70 < total score ≤ 198, 30% ≤ 10-year 
overall survival < 70%. Intermediate risk group: 70 < total score ≤ 198, 
30% ≤ 10-year overall survival < 70%. Poor risk group: total score ≥199, 
10-year overall survival <30%. The total score was calculated according to 
Fig. 2; †7-year OS in RARECAREnet cohort.
CI, confidence interval.
Figure 2
Kaplan–Meier overall survival curves according to the classification 
prognostic score in training set (panel A) and RARECAREnet and Italian 
validation sets (panels B and C, respectively). A full colour version of this 
figure is available at https://doi.org/10.1530/ERC-17-0489.
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in this cohort, and in particular, by the opportunity, for 
these patients, to access more effective treatments and 
be included into clinical trials with respect to unknown 
primary/midgut or lung NET patients (87.3% and 73% 
of patients including in the training set and RARECARE 
validation set, respectively). In addition, patients 
included in the Italian multicenter set were treated from 
2000 to 2015, while those in the training set were treated 
from 1988 to 2012 and those in the RARECAREnet 
from 2000 to 2007. Therefore, patients in the Italian 
multicenter set could have received a more refined 
diagnosis and treatment compared with others. Due to 
the marked variability and availability of treatments 
in recent decades and different countries, we did not 
evaluate the impact of medical treatments received by 
patients on survival. Moreover, since PRRT recently 
showed a prolongation of OS in midgut NET patients 
(Strosberg et al. 2017), while other available treatments 
Figure 3
Calibration plot for internal (panel A) and external (RARECAREnet and 
Italian testing set patients in panel B and C, respectively) validation of the 
stage IV well-differentiated neuroendocrine prognostic score 
classification (NEP-Score). The Kaplan–Meier overall survival probability in 
each prognostic group was plotted (y axis) against the corresponding 
NEP-Score predicted probability (x axis). The error bars are the Kaplan–
Meier 95% confidence intervals. The solid diagonal line is the reference 
line, indicating the probability of an ideal classification prognostic score 
(accordance between predicted and observed probabilities). OS, overall 
survival.
Figure 4
Kaplan–Meier overall survival curves according to the prognostic score 
classification and calibration plot (panel A and B, respectively) for Italian 
series cohort patients not treated with peptide receptor radionuclide 
therapy. A full colour version of this figure is available at https://doi.
org/10.1530/ERC-17-0489.
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did not (Rinke et al. 2009, Yao et al. 2016, 2017, Faivre 
et  al. 2017, Pavel et  al. 2017), we speculated that this 
effect could also be observed in pNET patients and that 
this could be another of the causes of overestimated OS 
in the multicentric Italian validation cohort.
Therefore, in order to partially address this issue, we 
conducted a subgroup analysis excluding patients who 
received PRRT. Despite the limited number of patients 
in this subgroup and the consequent poor precision 
of calibration analyses, we found a therapeutic factor 
able to prolong OS, since the calibration plot points 
are approaching the reference line (Fig.  4). Of note, 
calibration and discriminative ability are referred to 
different aspects of model performance and, as in our 
case, the slight deviance from the perfect calibration in 
the two validation cohorts (with a good parallelism of 
the curves with the reference line, indicating that the 
covariates’ effects were correctly estimated by the NEP-
Score model) does not affect the discriminative ability, 
which was comparable in the training and validation 
cohorts. Thus, NEP-Score can also be applied to stratify 
survival probability in different and heterogeneous 
groups of patients. We must however acknowledge some 
limitations of our study, including those inherent to any 
retrospective observational study with a long observation 
period (e.g., poor reporting of data). Moreover, although 
very recent studies have paved the way for a deeper 
investigation of molecular prognostic factors in NETs 
(Scarpa et al. 2017), at the moment of the conduction of 
the present analysis molecular prognostic factors for this 
class of neoplasms were not validated yet, and therefore, 
were not considered for the development of NEP-Score. 
Patients were recruited over different and prolonged time 
periods (1988–2012 in the training set), and therefore, 
we cannot rule out that improvement of care over time 
may have somehow biased our findings. Future studies 
could contribute to update NEP-Score in two ways: by 
simplifying it even more than it already is without lose in 
discriminative ability or by adding molecular prognostic 
factors, thus increasing discriminative ability.
Despite these limitations, we were able to develop, 
by analyzing a large population of patients, an easy 
and inexpensive scoring system, which might support 
clinicians in clinical decision-making. We acknowledge 
that our score is more complex than the commonly used 
approach of including patients with progressive disease 
over a specified time period (such as 6, 12 or 36 months). 
However, our score takes into account several different 
pieces of information that may allow to identify patients 
more suitable for clinical trials. Indeed, our score is based 
on a hard endpoint – OS – and includes several clinical 
variables associated with time to progression. Moreover, 
current treatment algorithms for the therapy of NET 
do not provide recommendations on the sequence of 
therapy. The challenge is to predict the aggressiveness of 
individual tumors in order to identify WDNET patients 
who will benefit from ‘early aggressive’ therapy and to 
minimize harm from the inadvertent overtreatment of 
patients with indolent disease. Therefore, we speculate 
that the stratification of patients according to NEP-Score 
may be useful in the definition of a tailored therapeutic 
strategy, e.g., by initiating an early intensive treatment 
(targeted therapies, chemotherapy or PRRT) in patients 
with poorer prognosis (i.e., ‘poor risk’ group) or saving 
more tolerable therapies like SSAs for those with indolent 
disease, who have a predicted longer survival (‘favorable 
risk group’) and may require long-lasting therapy. Indeed, 
a well-established tailored approach should be based on 
the proper evaluation of the risk of adverse events and the 
presence of comorbidities vs therapeutic strategy and life 
expectancy. Since treatment of NETs is often prolonged, 
it is crucial to avoid those mild-to-moderate adverse 
events which, when persisting, could lead to worsening of 
patient’s quality of life.
Clearly, further clinical trials are required to explain 
the precise strategy and the optimal specific sequence 
and timing of standard therapeutic options. This clinical 
classification prognostic score, validated in a large 
population of patients, may represent a useful tool for 
the design of prospective clinical trials aimed at assessing 
the effect of different treatments and their appropriate 
sequence in different risk groups of WDNET. Moreover, 
a future challenge will be to integrate biological and 
epigenetic characteristics of the tumors into well-tested 
prognostic models.
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